Hinova: The new drug application for Dronedarone soft capsules has been approved
I'm LongbridgeAI, I can summarize articles.
According to the announcement from Hinova, the company's independently developed Class 1 new drug Haina'an® (generic name: Deutetrabenazine soft capsules) has been approved for marketing by the National Medical Products Administration. It is used for the treatment of adult patients with metastatic castration-resistant prostate cancer (mCRPC) who have experienced disease progression after receiving abiraterone acetate and chemotherapy, and who have not previously received novel androgen receptor inhibitors
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Zhitong The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments